The global cough syrup market size reached US$ 5.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 7.3 Billion by 2028, exhibiting a growth rate (CAGR) of 4.11% during 2023-2028.
Cough syrup is a combination drug that is used to provide temporary relief from cough, common cold, hay fever and other respiratory allergies. It is manufactured using non-opioid cough suppressants, expectorants and antihistamine compounds to block the symptoms. The suppressants aid in alleviating the symptoms of dry cough by minimizing the activity of the cough reflex and reducing the urge to cough. The expectorants aid in treating cough with mucus by loosening the mucus, thereby making it easier to expel from the body. The antihistamines are used to relieve cough caused by minor throat or airway irritation. Cough syrups are usually prescribed by doctors or are available over-the-counter (OTC) in pharmacy stores in a wide variety of flavors, such as cherry, orange, honey and bubblegum.
Cough Syrup Market Trends:
The increasing prevalence of upper respiratory tract infection (URTI) and other respiratory disorders across the globe is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Cough syrup is primarily used for the treatment of dry cough developed due to the prolonged exposure to poor air quality, tobacco and indoor smoke and air pollution. In line with this, the rising health consciousness among the masses and convenient product availability in pharmacies and general stores are also contributing to the growth of the market. Additionally, various product innovations, such as the development of cough syrups with minimal side effects, are acting as other growth-inducing factors. Product manufacturers are developing variants fortified with natural herbs and ingredients with immunity-boosting effects. Other factors, including rising expenditure capacities of the consumers, along with significant growth in the pharmaceutical industry, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global cough syrup market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, age group and distribution channel.
Breakup by Product Type:
Breakup by Age Group:
Breakup by Distribution Channel:
Breakup by Region:
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Acella Pharmaceuticals LLC, Bayer AG, GlaxoSmithKline PLC, Johnson & Johnson, Pfizer Inc., Prestige Consumer Healthcare Inc., Reckitt Benckiser Group PLC, Sanofi, Sun Pharmaceutical Industries Limited and The Procter & Gamble Company.
Base Year of the Analysis
Product Type, Age Group, Distribution Channel, Region
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Acella Pharmaceuticals LLC, Bayer AG, GlaxoSmithKline PLC, Johnson & Johnson, Pfizer Inc., Prestige Consumer Healthcare Inc., Reckitt Benckiser Group PLC, Sanofi, Sun Pharmaceutical Industries Limited and The Procter & Gamble Company
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global cough syrup market was valued at US$ 5.7 Billion in 2022.
We expect the global cough syrup market to exhibit a CAGR of 4.11% during 2023-2028.
The sudden outbreak of the COVID-19 pandemic has led to the rising adoption of cough syrups to provide a relief from cough, hay fever, and other respiratory allergies, which are some of the common symptoms of the coronavirus infection.
The increasing prevalence of Upper Respiratory Tract Infection (URTI) and other respiratory disorders, along with the introduction of cough syrup with natural herbs, ingredients, and immunity-boosting effects, is primarily driving the global cough syrup market.
Based on the product type, the global cough syrup market can be categorized into expectorants, cough suppressants/antitussives, and combination medications. Currently, cough suppressants/antitussives account for the majority of the global market share.
Based on the age group, the global cough syrup market has been segregated into pediatric and adult, where adult currently holds the largest market share.
Based on the distribution channel, the global cough syrup market can be bifurcated into retail pharmacy, hospital pharmacy, and online pharmacy. Currently, retail pharmacy exhibits a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where Asia-Pacific currently dominates the global market.
Some of the major players in the global cough syrup market include Acella Pharmaceuticals LLC, Bayer AG, GlaxoSmithKline PLC, Johnson & Johnson, Pfizer Inc., Prestige Consumer Healthcare Inc., Reckitt Benckiser Group PLC, Sanofi, Sun Pharmaceutical Industries Limited, and The Procter & Gamble Company.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.